BACKGROUND:Postural tachycardia syndrome (POTS) induces disabling chronic orthostatic intolerance with an excessive increase in heart rate on standing, and many patients with POTS have low blood volume. Increasing blood volume is a promising approach to this problem. OBJECTIVE: To test the hypothesis that desmopressin (DDAVP) will attenuate the tachycardia and improve symptom burden in patients with POTS. METHODS: In this protocol, patients with POTS (n = 30) underwent acute drug trials withDDAVP 0.2 mg orally and placebo, on separate mornings, in a randomized crossover design. Blood pressure, heart rate, and symptoms were assessed while seated and after standing for up to 10 minutes prior to and hourly for 4 hours following study drug. RESULTS: The standing heart rate was significantly lower following DDAVP than placebo (101.9 ± 14.5 beats/min vs 109.2 ± 17.4 beats/min; P <.001). Standing blood pressure was not affected (P = .28). The symptom burden improved with DDAVP (from a score of 18 ± 18 arbitrary units [AU] to 13 ± 15 AU at 2 hours) compared with placebo (from 18 ± 17 AU to 19 ± 16 AU; P = .010). CONCLUSIONS:Oral DDAVP significantly attenuated tachycardia and improved symptoms in POTS. The safety profile of this approach would need to be examined before it can be recommended for routine treatment of these patients.
RCT Entities:
BACKGROUND:Postural tachycardia syndrome (POTS) induces disabling chronic orthostatic intolerance with an excessive increase in heart rate on standing, and many patients with POTS have low blood volume. Increasing blood volume is a promising approach to this problem. OBJECTIVE: To test the hypothesis that desmopressin (DDAVP) will attenuate the tachycardia and improve symptom burden in patients with POTS. METHODS: In this protocol, patients with POTS (n = 30) underwent acute drug trials with DDAVP 0.2 mg orally and placebo, on separate mornings, in a randomized crossover design. Blood pressure, heart rate, and symptoms were assessed while seated and after standing for up to 10 minutes prior to and hourly for 4 hours following study drug. RESULTS: The standing heart rate was significantly lower following DDAVP than placebo (101.9 ± 14.5 beats/min vs 109.2 ± 17.4 beats/min; P <.001). Standing blood pressure was not affected (P = .28). The symptom burden improved with DDAVP (from a score of 18 ± 18 arbitrary units [AU] to 13 ± 15 AU at 2 hours) compared with placebo (from 18 ± 17 AU to 19 ± 16 AU; P = .010). CONCLUSIONS: Oral DDAVP significantly attenuated tachycardia and improved symptoms in POTS. The safety profile of this approach would need to be examined before it can be recommended for routine treatment of these patients.
Authors: Jordan A Brewster; Emily M Garland; Italo Biaggioni; Bonnie K Black; John F Ling; Cyndya A Shibao; David Robertson; Satish R Raj Journal: Clin Sci (Lond) Date: 2012-01 Impact factor: 6.124
Authors: Qi Fu; Tiffany B Vangundy; M Melyn Galbreath; Shigeki Shibata; Manish Jain; Jeffrey L Hastings; Paul S Bhella; Benjamin D Levine Journal: J Am Coll Cardiol Date: 2010-06-22 Impact factor: 24.094
Authors: Kanika Bagai; Yanna Song; John F Ling; Beth Malow; Bonnie K Black; Italo Biaggioni; David Robertson; Satish R Raj Journal: J Clin Sleep Med Date: 2011-04-15 Impact factor: 4.062
Authors: Lisa M Benrud-Larson; Melanie S Dewar; Paola Sandroni; Teresa A Rummans; Jennifer A Haythornthwaite; Phillip A Low Journal: Mayo Clin Proc Date: 2002-06 Impact factor: 7.616
Authors: Satish R Raj; Bonnie K Black; Italo Biaggioni; Sachin Y Paranjape; Maricelle Ramirez; William D Dupont; David Robertson Journal: Circulation Date: 2009-08-17 Impact factor: 29.690
Authors: Lisa M Benrud-Larson; Paola Sandroni; Jennifer A Haythornthwaite; Teresa A Rummans; Phillip A Low Journal: Health Psychol Date: 2003-11 Impact factor: 4.267
Authors: Victor C Nwazue; Amy C Arnold; Vidya Raj; Bonnie K Black; Italo Biaggioni; Sachin Y Paranjape; Carlos Orozco; William D Dupont; David Robertson; Satish R Raj Journal: Clin Exp Pharmacol Physiol Date: 2014-05 Impact factor: 2.557
Authors: Julian M Stewart; Jeffrey R Boris; Gisela Chelimsky; Phillip R Fischer; John E Fortunato; Blair P Grubb; Geoffrey L Heyer; Imad T Jarjour; Marvin S Medow; Mohammed T Numan; Paolo T Pianosi; Wolfgang Singer; Sally Tarbell; Thomas C Chelimsky Journal: Pediatrics Date: 2017-12-08 Impact factor: 7.124
Authors: Elizabeth A Green; Bonnie K Black; Italo Biaggioni; Sachin Y Paranjape; Kanika Bagai; Cyndya Shibao; Mirian C Okoye; William D Dupont; David Robertson; Satish R Raj Journal: Cardiovasc Ther Date: 2014-06 Impact factor: 3.023
Authors: Ashley L Wagoner; Hossam A Shaltout; John E Fortunato; Debra I Diz Journal: Am J Physiol Heart Circ Physiol Date: 2015-11-25 Impact factor: 4.733
Authors: Philip L Mar; Vidya Raj; Bonnie K Black; Italo Biaggioni; Cyndya A Shibao; Sachin Y Paranjape; William D Dupont; David Robertson; Satish R Raj Journal: J Psychopharmacol Date: 2013-11-13 Impact factor: 4.153